{"id":745308,"date":"2016-10-26T12:31:00","date_gmt":"2016-10-26T12:31:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-prices-eur-1-0-billion-debt-offering\/"},"modified":"2025-11-07T01:25:34","modified_gmt":"2025-11-07T06:25:34","slug":"merck-prices-eur-1-0-billion-debt-offering","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-prices-eur-1-0-billion-debt-offering\/","title":{"rendered":"Merck Prices EUR 1.0 Billion Debt Offering"},"content":{"rendered":"<p>\n      Merck &amp; Co., Inc., (NYSE:MRK), known as MSD outside the United States<br \/>\n      and Canada, priced today a EUR 1.0 billion public offering of two series<br \/>\n      of Euro-denominated senior unsecured notes (collectively, the \u201cNew<br \/>\n      Notes\u201d). Based on Oct. 21, 2016, closing exchange rates the EUR 1.0<br \/>\n      billion equates to approximately $1.087 billion. The notes include:\n    <\/p>\n<p class=\"bwalignc\">\n      EUR 500 million of 0.500% notes due Nov. 2024<br \/>EUR 500 million of<br \/>\n      1.375% notes due Nov. 2036\n    <\/p>\n<p>\n      Merck intends to use the net proceeds from the offering for general<br \/>\n      corporate purposes, including without limitation repayment of<br \/>\n      outstanding commercial paper borrowings and other indebtedness with<br \/>\n      upcoming maturities. The offering is expected to close on Nov. 2, 2016,<br \/>\n      subject to customary closing conditions. BNP Paribas, Citigroup Global<br \/>\n      Markets Limited, and Merrill Lynch International are acting as the<br \/>\n      active joint book-running managers for the offering.\n    <\/p>\n<p>\n      The offering of the New Notes is being made pursuant to an effective<br \/>\n      shelf registration statement (including a base prospectus) filed with<br \/>\n      the Securities and Exchange Commission (SEC). The offering may be made<br \/>\n      only by means of a prospectus and related prospectus supplement, copies<br \/>\n      of which may be obtained by calling BNP Paribas at (800) 854-5674,<br \/>\n      Citigroup Global Markets Limited at (800) 831-9146, or Merrill Lynch<br \/>\n      International at (800) 294-1322. An electronic copy of the registration<br \/>\n      statement and prospectus supplement, together with the base prospectus,<br \/>\n      is available on the SEC\u2019s website at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51447690&amp;newsitemid=20161026006526&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=1&amp;md5=8843cf0e19678233cfcf1c85e62d5992\" rel=\"nofollow\">www.sec.gov<\/a>.\n    <\/p>\n<p>\n      This press release does not constitute an offer to sell or a<br \/>\n      solicitation of an offer to buy the securities described herein, nor<br \/>\n      shall there be any sale of these securities in any state or jurisdiction<br \/>\n      in which such an offer, solicitation or sale would be unlawful prior to<br \/>\n      registration or qualification under the securities laws of any such<br \/>\n      jurisdiction.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For 125 years, Merck has been a global health care leader working to<br \/>\n      help the world be well. Merck is known as MSD outside the United States<br \/>\n      and Canada. Through our prescription medicines, vaccines, biologic<br \/>\n      therapies and animal health products, we work with customers and operate<br \/>\n      in more than 140 countries to deliver innovative health solutions. We<br \/>\n      also demonstrate our commitment to increasing access to health care<br \/>\n      through far-reaching policies, programs and partnerships.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. Such statements may include, but are not limited to,<br \/>\n      the company\u2019s ability to complete the offering and the company\u2019s<br \/>\n      expectations for the use of proceeds from the offering. These statements<br \/>\n      are based upon the current beliefs and expectations of the company\u2019s<br \/>\n      management and are subject to significant risks and uncertainties. If<br \/>\n      underlying assumptions prove inaccurate or risks or uncertainties<br \/>\n      materialize, actual results may differ materially from those set forth<br \/>\n      in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2015 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51447690&amp;newsitemid=20161026006526&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=2&amp;md5=5b9fa8f7827642b3c11e2b4fa3770fe6\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20161026006526r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" \/><br \/>\n<span class=\"bwct31415\" \/><br \/>\n<\/span><\/p>\n<p>       Merck &amp; Co., Inc.<br \/>Media:<br \/>Lainie Keller, 908-236-5036<br \/>Tracy        Ogden, 267-305-2301<br \/>or<br \/>Investors:<br \/>Teri Loxam, 908-740-1986<br \/>Amy        Klug, 908-740-1898     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck &amp; Co., Inc., (NYSE:MRK), known as MSD outside the United States and Canada, priced today a EUR 1.0 billion public offering of two series of Euro-denominated senior unsecured notes (collectively, the \u201cNew Notes\u201d). Based on Oct. 21, 2016, closing exchange rates the EUR 1.0 billion equates to approximately $1.087 billion. The notes include: EUR 500 million of 0.500% notes due Nov. 2024 EUR 500 million of 1.375% notes due Nov. 2036 Merck intends to use the net proceeds from the offering for general corporate purposes, including without limitation repayment of outstanding commercial paper borrowings and other indebtedness with upcoming maturities. The offering is expected to close on Nov. 2, 2016, subject to customary closing conditions. BNP Paribas, Citigroup Global Markets Limited, and Merrill Lynch International are acting as the active joint book-running managers for the offering. The offering of the New Notes is being made pursuant to an effective shelf registration statement<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,52,64,289],"class_list":["post-745308","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-financial-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Prices EUR 1.0 Billion Debt Offering - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-prices-eur-1-0-billion-debt-offering\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Prices EUR 1.0 Billion Debt Offering - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck &amp; Co., Inc., (NYSE:MRK), known as MSD outside the United States and Canada, priced today a EUR 1.0 billion public offering of two series of Euro-denominated senior unsecured notes (collectively, the \u201cNew Notes\u201d). Based on Oct. 21, 2016, closing exchange rates the EUR 1.0 billion equates to approximately $1.087 billion. The notes include: EUR 500 million of 0.500% notes due Nov. 2024 EUR 500 million of 1.375% notes due Nov. 2036 Merck intends to use the net proceeds from the offering for general corporate purposes, including without limitation repayment of outstanding commercial paper borrowings and other indebtedness with upcoming maturities. The offering is expected to close on Nov. 2, 2016, subject to customary closing conditions. BNP Paribas, Citigroup Global Markets Limited, and Merrill Lynch International are acting as the active joint book-running managers for the offering. The offering of the New Notes is being made pursuant to an effective shelf registration statement\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-prices-eur-1-0-billion-debt-offering\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-prices-eur-1-0-billion-debt-offering\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-prices-eur-1-0-billion-debt-offering\\\/\",\"name\":\"Merck Prices EUR 1.0 Billion Debt Offering - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2016-10-26T12:31:00+00:00\",\"dateModified\":\"2025-11-07T06:25:34+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-prices-eur-1-0-billion-debt-offering\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-prices-eur-1-0-billion-debt-offering\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-prices-eur-1-0-billion-debt-offering\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Prices EUR 1.0 Billion Debt Offering\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Prices EUR 1.0 Billion Debt Offering - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-prices-eur-1-0-billion-debt-offering\/","og_locale":"en_US","og_type":"article","og_title":"Merck Prices EUR 1.0 Billion Debt Offering - Merck.com","og_description":"Merck &amp; Co., Inc., (NYSE:MRK), known as MSD outside the United States and Canada, priced today a EUR 1.0 billion public offering of two series of Euro-denominated senior unsecured notes (collectively, the \u201cNew Notes\u201d). Based on Oct. 21, 2016, closing exchange rates the EUR 1.0 billion equates to approximately $1.087 billion. The notes include: EUR 500 million of 0.500% notes due Nov. 2024 EUR 500 million of 1.375% notes due Nov. 2036 Merck intends to use the net proceeds from the offering for general corporate purposes, including without limitation repayment of outstanding commercial paper borrowings and other indebtedness with upcoming maturities. The offering is expected to close on Nov. 2, 2016, subject to customary closing conditions. BNP Paribas, Citigroup Global Markets Limited, and Merrill Lynch International are acting as the active joint book-running managers for the offering. The offering of the New Notes is being made pursuant to an effective shelf registration statement","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-prices-eur-1-0-billion-debt-offering\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:34+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-prices-eur-1-0-billion-debt-offering\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-prices-eur-1-0-billion-debt-offering\/","name":"Merck Prices EUR 1.0 Billion Debt Offering - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2016-10-26T12:31:00+00:00","dateModified":"2025-11-07T06:25:34+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-prices-eur-1-0-billion-debt-offering\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-prices-eur-1-0-billion-debt-offering\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-prices-eur-1-0-billion-debt-offering\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Prices EUR 1.0 Billion Debt Offering"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"f466f880-558d-4f4d-9ba1-9d6785bf66a8","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745308","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745308\/revisions"}],"predecessor-version":[{"id":3674717,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745308\/revisions\/3674717"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745308"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745308"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}